AdCD40L

BIOLOGICAL2 trials

Sponsors

Uppsala University

Conditions

Bladder CancerMalignant Melanoma

Phase 1

Safety Study on AdCD40L Gene Therapy for Bladder Cancer

CompletedNCT00891748

Uppsala UniversityBladder Cancer

Start: 2006-11-30End: 2009-10-31Target: 12Updated: 2010-01-18

Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors

CompletedNCT01455259

Uppsala UniversityMalignant Melanoma

Start: 2011-09-30End: 2016-01-31Updated: 2016-02-17

Related Papers

Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours

Annals of Oncology2018-10-01

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Journal of Translational Medicine2017-04-2056 citations